Abstracts Archive - Page 930 of 2425 - ACR Meeting Abstracts

Abstract Number: 2575 • 2019 ACR/ARP Annual Meeting
Electronic Monitoring of Medication Adherence in Young Adults with Childhood-Onset Systemic Lupus Erythematosus over 12 Weeks
Onengiya Harry¹, Tracy Ting ² and Jennifer Huggins ², ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Young adults with childhood-onset lupus (cSLE) are 20 times more likely to die compared to healthy age- and gender-matched counterparts. Their clinical course is…
Abstract Number: 2576 • 2019 ACR/ARP Annual Meeting
Clinical Evidence Supporting Therapeutic Potential of Activating the Immune Checkpoint Receptor BTLA in SLE
Matthew Linnik¹, Adam Godzik ², Lukasz Jaroszewski ², Carl Ware ² and Andrew Vendel ¹, ¹Lilly Biotechnology Center, San Diego, CA, ²Sanford Burnham Prebys Medical Research Institute, La Jolla, CA
Background/Purpose: Background/Purpose: Immune checkpoint inhibitors have demonstrated durable benefit in some cancer patients. However, checkpoint inhibitors are also associated with new onset autoimmune adverse events. …
Abstract Number: 2577 • 2019 ACR/ARP Annual Meeting
SLE Disease Activity May Be Associated with Choroidal Thickness
Iris Lee¹, Brigid Marshall ¹, Prabha Ranganathan ², Seth Eisen ³, Rithwick Rajagopal ¹, Alfred Kim ³ and Tingting Li ¹, ¹Washington University in St Louis, St Louis, ²Washington University in St Louis, St Louis, MO, ³Washington University School of Medicine, Saint Louis, MO
Background/Purpose: SLE is an autoimmune disease with widespread organ involvement. High disease activity has previously been associated with higher risk of organ damage and mortality.…
Abstract Number: 2578 • 2019 ACR/ARP Annual Meeting
Effect of Omega-3 Fatty Acids on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
Ali Duarte Garcia¹, Elena Myasoedova ¹, Paras Karmacharya ¹, Cynthia Crowson ² and Kenneth Warrington ³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester, ³Mayo Clinic Rochester, Rochester, MN
Background/Purpose: Omega-3 fatty acids may have anti-inflammatory properties. In animal models of systemic lupus erythematosus (SLE) Omega-3 fatty acids decrease autoantibody levels, reduce inflammatory markers…
Abstract Number: 2579 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity
Eric Liu¹ and Andras Perl ², ¹SUNY Upstate University Medical Center, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in our field of work with retinal toxicity being a known possible long-term side effect of the…
Abstract Number: 2580 • 2019 ACR/ARP Annual Meeting
Pharmacotherapies Targeting Type 2 SLE Symptoms
Raeann Whitney¹, Amanda Eudy ¹, Megan Clowse ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, David Pisetsky ², Kai Sun ¹, Rebecca Sadun ¹ and Jennifer Rogers ¹, ¹Duke University, Durham, ²Duke University, Durham VAMC, Durham
Background/Purpose: We propose categorizing lupus activity to better align with patient experience: Type 1 SLE activity includes classic symptoms such as arthritis and nephritis; Type…
Abstract Number: 2581 • 2019 ACR/ARP Annual Meeting
Clinical Impact of Decreasing Hydroxychloroquine Dose According to the 2016 American Academy of Ophthalmology Guidelines in Patients with Systemic Lupus Erythematosus
Nicolle Medina-Cintrón¹, Ileana Vázquez-Otero ¹, Mariangelí Arroyo-Ávila ¹, Lorena González-Sepúlveda ¹ and Luis Vilá ¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Hydroxychloroquine (HCQ) is one of the main drugs used for the treatment of systemic lupus erythematosus (SLE). Nonetheless, HCQ-induced retinal toxicity remains a major…
Abstract Number: 2582 • 2019 ACR/ARP Annual Meeting
Incidence of Antimalarials-Induced Retinopathy in Inflammatory Rheumatic Diseases, Using OCT and Visual Field Test : A Systematic Review and Meta-analysis
Helene de Cagny¹, Jacques Morel ², Cécile Gaujoux-Viala ³, Bernard Combe ⁴ and Cédric Lukas ⁵, ¹University Hospital of Montpellier, Montpellier, France, ²CHU MONTPELLIER, MONTPELLIER, France, ³Nîmes University Hospital, Nîmes, France, ⁴CHU Montpellier, Montpellier University, Montpellier, France, ⁵Rheumatology department, CHU Montpellier, Univ Montpellier, Montpellier, France
Background/Purpose: Antimalarials (AM) are frequently used as first-line therapy in mild inflammatory diseases, because of a good benefit/risk ratio. Their most severe side effect is…
Abstract Number: 2583 • 2019 ACR/ARP Annual Meeting
Prevalence and Risk Factors of Herpes Zoster Reactivation in Patients with Biopsy Proven Lupus Nephritis Undergoing Immunosuppressive Therapies
Chi Chiu Mok¹, Kar Li Chan ², Sau Mei Tse ² and Ling Yin Ho ², ¹Department of Medicine, Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the prevalence of Herpes Zoster (HZ) reactivation in patients with biopsy confirmed lupus nephritis (LN) undergoing immunosuppressive therapies.Methods: Patients who had biopsy…
Abstract Number: 2584 • 2019 ACR/ARP Annual Meeting
Management of Cutaneous Manifestations of Lupus Erythematosus: A Systematic Review
Jessica Fairley¹, Shereen Oon ², Amanda Saracino ³ and Mandana Nikpour ², ¹Monash University, Melbourne, Australia, ²St Vincent's Hospital, Melbourne; The University of Melbourne, Melbourne, Australia, ³University College London, London, United Kingdom
Background/Purpose: Cutaneous lupus erythematosus (CLE), occurring with or without systemic lupus erythematosus (SLE), is a group of inflammatory skin diseases that can be very debilitating,…
Abstract Number: 2585 • 2019 ACR/ARP Annual Meeting
A Comparison of Risk of Ovarian Failure Following Intravenous Cyclophosphamide Therapy in Juvenile versus Adult Systemic Lupus Erythematosus
shefali sharma¹, Hemanth Chinthala ², siddharth Jain ², Arghya Chattopadhyay ², Pooja Bahl ², Varun Dhir ³, naresh Sachdeva ² and Surjit Singh ⁴, ¹Dr., Chandigarh, Chandigarh, India, ²Post Graduate Institute of Medical Education and Research, chandigarh, Chandigarh, India, ³Post Graduate Institute of Medical Education and Research, Chandigarh, India, ⁴Allergy Immunology Unit, Department pf Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Premature ovarian failure is a dreaded complication of cyclophosphamide (CYC). It is related to age of initiation of therapy and the cumulative dose. This…
Abstract Number: 2586 • 2019 ACR/ARP Annual Meeting
Clinical Characteristics and Survival in Systemic Sclerosis-mixed Connective Tissue Disease and Systemic Sclerosis-overlap Syndrome
Jessica Fairley¹, Dylan Hansen ², Susanna Proudman ³, Joanne Sahhar ¹, Gene-Siew Ngian ¹, Jenny Walker ⁴, Gemma Strickland ², Michelle Wilson ², Kathleen Morrisroe ², Nava Ferdowski ², Gabor Major ⁵, Janet Roddy ⁶, Wendy Stevens ² and Mandana Nikpour ⁷, ¹Monash University, Melbourne, Australia, ²St Vincent's Hospital, Melbourne, Melbourne, Australia, ³University of Adelaide, Adelaide, Australia, ⁴Royal Adelaide Hospital, Melbourne, Australia, ⁵Royal Newcastle Centre John Hunter Hospital, Newcastle, Australia, ⁶Fiona Stanley Hospital, Perth, Australia, ⁷St Vincent's Hospital, Melbourne; The University of Melbourne, Melbourne, Australia
Background/Purpose: Mixed connective tissue disease (MCTD) is defined by presence of anti-RNP antibody together with 3 or more of swollen hands, synovitis, myositis, Raynaud phenomenon…
Abstract Number: 2587 • 2019 ACR/ARP Annual Meeting
Prognostic Role of Measurement of Renal Resistive Index in Systemic Sclerosis
shefali sharma¹, Arghya Chattopadhyay ², siddharth Jain ², Varun Dhir ³, mahesh Prakash ³ and manish Rathi ², ¹Dr., Chandigarh, Chandigarh, India, ²Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India, ³Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Spectrum of vascular involvement in systemic sclerosis (SSc) is diverse like Raynaud’s phenomenon, digital ulcers, pulmonary hypertension and renal disease. Recognition of markers of…
Abstract Number: 2588 • 2019 ACR/ARP Annual Meeting
Myositis-specific and -associated Antibodies in Systemic Sclerosis: Prevalence and Clinical Associations
Amélie Leurs ¹, Sylvain Dubucquoi ¹, François Machuron ¹, Maité Balden ¹, Florence Renaud ¹, Stéphanie Rogeau ¹, Benjamin Lopez ², Marc LAMBERT ³, Sandrine Morell-Dubois ⁴, Hélène Maillard ⁴, Hélène Behal ¹, Eric Hachulla ⁵, David Launay ¹ and Vincent Sobanski¹, ¹CHU Lille, Lille, France, ²Institute of Immunology, CHU Lille, University of Lille, Lille, France, ³Lille University Hospital, Lille, France, ⁴Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, ⁵Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France
Background/Purpose: In systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM), auto-antibodies are used in daily practice as potent biomarkers of clinical phenotypes. This study aimed…
Abstract Number: 2589 • 2019 ACR/ARP Annual Meeting
Searching the Calcinosis Signature: A Case Control Study Analyzing Limited Systemic Sclerosis Female Patients with and Without Calcinosis, Paired by Disease Duration, Age and Body Mass Index
Marilia Sampaio-Barros ¹, Lorena Castelo-Branco ¹, Liliam Takayama ¹, Marco Pontes-Filho ¹, Percival Degrava Sampaio-Barros ² and Rosa Pereira³, ¹University of Sao Paulo, Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Brazil, Sao Paulo, Brazil, ³Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil
Background/Purpose: Calcinosis usually represents a late manifestation of limited systemic sclerosis (lSSc), inducing chronic calcifications that lead to significant impairment in the quality of life.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].